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Abstract
Background: Concerns are often raised about the accuracy of microarray technologies and the
degree of cross-platform agreement, but there are yet no methods which can unambiguously
evaluate precision and sensitivity for these technologies on a whole-array basis.
Results: A methodology is described for evaluating the precision and sensitivity of whole-genome
gene expression technologies such as microarrays. The method consists of an easy-to-construct
titration series of RNA samples and an associated statistical analysis using non-linear regression.
The method evaluates the precision and responsiveness of each microarray platform on a whole-
array basis, i.e., using all the probes, without the need to match probes across platforms. An
experiment is conducted to assess and compare four widely used microarray platforms. All four
platforms are shown to have satisfactory precision but the commercial platforms are superior for
resolving differential expression for genes at lower expression levels. The effective precision of the
two-color platforms is improved by allowing for probe-specific dye-effects in the statistical model.
The methodology is used to compare three data extraction algorithms for the Affymetrix
platforms, demonstrating poor performance for the commonly used proprietary algorithm relative
to the other algorithms. For probes which can be matched across platforms, the cross-platform
variability is decomposed into within-platform and between-platform components, showing that
platform disagreement is almost entirely systematic rather than due to measurement variability.
Conclusion: The results demonstrate good precision and sensitivity for all the platforms, but
highlight the need for improved probe annotation. They quantify the extent to which cross-
platform measures can be expected to be less accurate than within-platform comparisons for
predicting disease progression or outcome.
Background
In recent years there has been a rapidly growing under-
standing of how gene expression reflects and determines
biological states. This has come about through the wide-
spread use of microarray expression profiling [1]. Yet
there have been concerns about the accuracy and repro-
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ducibility of the technology. Some early studies reported
poor reproducibility and dramatic differences between
platforms [2-5]. Although other studies have generally
reported better accuracy and agreement [6-8], especially
later studies using more developed statistical methods [9-
12], the early concern has contributed to an explosion in
the number of publications comparing microarray plat-
forms or assessing microarray accuracy.
Despite the growing number of publications, only a lim-
ited number of methods are available to assess the accu-
racy of genome-scale expression platforms. Before
discussing the strengths and weakness of the various strat-
egies, it is necessary to dissect exactly what is meant by
accuracy. There are several dimensions to platform accu-
racy. The first major dimension is consistency, i.e., the
ability of the platform to agree with itself. This can be fur-
ther divided into reproducibility or precision on one
hand, and dynamic range or sensitivity on the other.
These features determine the ability of the platform to dis-
tinguish differentially expressed transcripts from those
which are not. The sensitivity can be further examined to
check whether the measured probe intensities increase
linearly with transcript expression level. This determines
the ability of the platform to return accurate estimates of
the fold changes for differentially expression genes. The
second major dimension is probe annotation. Accurate
annotation determines the ability of the platform to agree
with independent measures of differential expression for
the same genes. It might be for example that a microarray
platform accurately measures the expression level for
some gene, but the probe is incorrectly annotated as
another gene. Another possibility is that two microarray
platforms might both accurately measure expression for
the correct gene, but might nevertheless disagree because
they respond to different splice-variants or isoforms of
that gene [9,13-16]. Annotation accuracy is likely to
improve for all platforms as knowledge of the genome
improves. We can view self-consistency as the innate accu-
racy of the platform because it can be improved only by a
change in the underlying technology.
Many platform comparison articles use variability
between technical replicates to measure precision
[4,6,10,15-22], but this doesn't measure sensitivity or lin-
earity. To measure sensitivity, it is necessary to introduce
genes which are known to be differentially expressed. PCR
is the traditional method for validating microarray discov-
eries, so some studies use quantitative PCR to determine
the true differential expression status for a subset of genes
[3,7,9,10,13,23-26]. This approach is practical only for a
small proportion of the probes, and has some other disad-
vantages which are discussed below. Another method of
introducing known fold changes is to spike-in a small
number of artificial genes into the RNA sample at known
concentrations [17,27-29]. This technique requires that
alien control probes be printed onto the arrays and the
corresponding transcripts spiked into the RNA samples
before labeling and hybridization. Spike-in controls how-
ever are inevitably platform specific and hence are more
suited to comparing different processing methods for a
given platform than for comparing different platforms.
Even for a given platform, spike-in controls suffer from a
number of shortcomings. Only a small number of distinct
transcripts can be spiked-in and these are often at a higher
message abundance than the endogenous genes and at
relatively large fold changes. Finally, the fact that the
spike-in RNA is not extracted with the main RNA sample
and has to be added separately means that the spike-in
probes will not follow the same intensity-dependent nor-
malization curve as the regular probes. This means that
the spike-in probes will generally need to be normalized
separately to the other probes and will not necessarily be
representative of the precision of the other probes.
Most platform comparison studies begin by matching
probes between platforms, and then measuring the agree-
ment between platforms for the common genes [4,6-
10,12,15,16,19-22,25,30-33]. Although natural, this
approach suffers from a number of problems. Firstly,
there is no perfect or unambiguous strategy for matching
probes. Matching on UniGene ID is clearly insufficient
because each platform may have multiple probes with
possibly different expression profiles mapped to the same
ID. The same problem applies to other gene classification
systems. More detailed sequence analysis may attempt to
position the probes at particular loci in the genome
[24,30], but even so an unambiguous matching of probes
between platforms is highly unlikely. When platforms dis-
agree, one cannot easily identify the source of disagree-
ment, whether this is due to innate imprecision of the
platforms or incorrect annotation. More basically, when
two platforms disagree the comparison does not tell us
which platform is correct, or even if either is correct. Even
the validation of microarray results by PCR can be subject
to these problems, especially if the splice variants for the
gene in question are not completely described.
A small number of studies have used a dilution series of
RNA samples to construct samples with a range of fold
changes [27,28,32,34]. Two other studies have taken the
approach mixing mRNA from two sources in known
quantities for the same purpose [16,35].
In this article we use a series of mixed mRNA samples and
introduce a more systematic method of analysis. Mixtures
of mRNA were derived from two cell lines in varying pro-
portions to cover a large dynamic range in gene expres-
sion. A statistical methodology is introduced for
evaluating the precision, sensitivity and linearity of micro-BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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array platforms. The novel design allows the series of
arrays to be analyzed as a whole. The mixture series give
predictable changes in fold change against which the
actual pattern of observed log-ratios can be compared.
There are several advantages to this design. Firstly, each
microarray platform is evaluated on a whole-array basis.
Every probe on the arrays adds information in assessing
the precision of the platform as each probe will behave
according to the mixtures series. Secondly, there is no
need to match probes across platforms as each platform
yields its own measure. On the other hand, if the addi-
tional step of matching probes across platforms is per-
formed, then our method provides a decomposition of
variability into within- and between-platform compo-
nents for each gene. This provides, for the first time, a
quantitative assessment of the degree of systematic disa-
greement between the platforms. Our method could be
applied to evaluate the precision of any whole-genome
gene expression technology, not only microarrays.
We use our methodology to assess and compare four
widely used microarray platforms: two commercial plat-
forms, Affymetrix and Agilent, and two academically pro-
duced platforms, spotted cDNA and oligonucleotide
arrays. This selection includes three two-color platforms
and one single-channel platform (Affymetrix). Our com-
parison includes careful consideration of special issues
which affect the different technologies including dye-
effects for the two-color platforms and experimental
design differences between the two-color and single-chan-
nel platforms.
Our intention is to evaluate the best-case scenario for each
platform rather than to evaluate laboratory to laboratory
variation as several other studies have done [10,29,31,36].
Hence we hybridized all the two-color microarrays in a
single experienced laboratory.
Of equal importance as the cross-platform issues is the
evaluation of alternative data processing algorithms for a
given platform. Pre-processing algorithms by which
expression measures are quantified from microarray
images include background correction, normalization
and summarization methods [37-39]. There is a slowly
emerging appreciation in the literature of the size of the
noise reduction that can be achieved by state-of-the-art
pre-processing methods [16,27-29,32,34,40,41]. For this
study we used what we consider to be best-practice pre-
processing methods for each platform. Our data and asso-
ciated statistical analysis provide an objective means to
compare different pre-processing methods for each plat-
form. To illustrate this we compare several popular meth-
ods of pre-processing Affymetrix GeneChip expression
values and show that the method used in our study per-
forms better than the alternatives.
Results
The titration series design
Six RNA mixes were prepared ranging from pure MCF7
(A1) through four mixtures of MCF7 and Jurkat (A2–A5)
to pure Jurkat (A6) (Table 1). For each of the three two-
color platforms, twelve arrays were hybridized (Figure 1).
Each of the six RNA mixes was compared to pure Jurkat
(B), with a dye-swap pair of arrays used for each compar-
ison. For the single channel platform, fourteen arrays were
hybridized, two for each of RNA mixes A1–A6 and B. The
rationale for this design is that the comparison of pure
RNAs A1 vs B should show considerable differential
expression and can be used to evaluate the responsiveness
or sensitivity of the platforms, while the same vs same
comparison A6 vs B should show no differential expres-
sion and can be used to evaluate the variability or specifi-
city of the platforms. The graduated mixes A2–A5 can be
used to evaluate the ability of each platform to faithfully
track fold changes as the relative expression changes. Our
analysis is in two major parts. First we examine the preci-
sion, i.e., the repeatability, of each platform individually.
This analysis uses all non-control probes on the arrays.
This analysis does not attempt to match probes between
platforms but simply assumes each platform contains a
comparable selection of probes. Later we do match probes
across the four platforms, to the extent that is possible,
and examine the concordance of the four platforms on
these common genes.
Figure 2 shows a representative selection of MA-plots for
arrays in the experiment. The rows of the plot correspond
to the RNA mixes A1, A3, A5 and A6 respectively and the
four columns to the four platforms. For the two-color
platforms, each MA-plot displays the relationship
between the log-ratios (M-values) and log-intensities (A-
values) for one array [42]. For the single-channel plat-
form, each MA-plot is constructed by comparing all the
log-intensities (E-values) of one array to the average log-
intensities of the two B arrays [43]. The top row corre-
Table 1: Mixing proportions used for titration series
Sample MCF7 c Jurkat 1-c
A1 100% 0%
A2 94% 6%
A3 88% 12%
A4 76% 24%
A5 50% 50%
A6 0% 100%
B 0% 100%
Samples A1 through A6 were created by mixing total mRNA from 
MCF7 breast epithelial cells with mRNA derived from the Jurkat T 
cell line in the proportions shown. The sample B was used as a 
reference RNA in all two-color hybridizations (spotted cDNA, 
spotted oligonucleotide and Agilent). For Affymetrix hybridizations, 
samples A1 through B were hybridized independently.BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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sponds to the pure MCF7 vs Jurkat comparison (A1 vs B),
the second row to 88% MCF7 vs Jurkat (A3 vs B), the third
row to 50% MCF7 vs Jurkat (A5 vs B) and the bottom row
is the Jurkat vs Jurkat comparison (A6 vs B). The plots are
orientated so that positive M-values correspond to higher
expression in MCF7 and negative M-values correspond to
higher expression in Jurkat. An ideal microarray platform
would show substantial differential expression on the top
row and successively decreasing differential expression
going down the figure. The MA-plots in the bottom row
should ideally show horizontal lines at M = 0 with no ver-
tical variation at all. All four microarray platforms show
this qualitative behavior with considerable spread of M-
values above and below the zero line in the top row and
very little variation at the bottom of the figure. The M-val-
ues for the Agilent and Affymetrix platforms are particu-
larly tight around M = 0 in the bottom plots while the
spotted arrays show somewhat more variation from M =
0. Looking more closely at the Agilent and Affymetrix col-
umns, all the Affymetrix plots show more vertical varia-
tion than the corresponding Agilent plots, suggesting that
the Affymetrix platform is more responsive than the Agi-
lent, returning larger fold changes, but is also more noisy.
Nonlinear regressions
For each probe p, let Fp be the intensity corresponding to
the expression level of the corresponding transcript in
MCF7 and let Jp be the intensity corresponding to its
expression in Jurkat. If c is the proportion of MCF7 in a
particular RNA mix, and if the observed intensity is pro-
portional to expression, then the intensity of the mix
should be cFp + (1 - c)Jp. Also let Rp = Fp/Jp be the expression
ratio (fold change) between MCF7 and Jurkat for that
probe. The fold change between the RNA mix and the Jur-
kat reference should be {cFp + (1 - c)Jp}/Jp = cRp + 1 - c. This
shows that, although we do not know the true values of Fp
or Jp for any gene, the log-expression and log-ratio values
must change in a predictable way across the titration
series.
For the single-channel platform, let Epj be the normalized
log-intensity for probe p and array j, j = 1,...,14. The theo-
retical log-intensity for probe p and array j is
αpj = log2{cjFp + (1 - cj)Jp}
where cj is the proportion of MCF7 in the RNA mix used
for array j. The observed log-intensity Epj can be repre-
sented as
Epj = log2(Mixture) = αpj + εpj   (1)
where εpj represents measurement error. We assume that
the εpj are independent with mean zero and with probe
dependent standard deviations ϕp. For the two-color plat-
forms, let Mpi be the normalized log-ratio for probe p on
array i, i = 1,...,12. The theoretical log-ratio for probe p and
array i is
βpi = log2(ciRp + 1 - ci)
where ci is the proportion of MCF7 in RNA mix used for
array i. The observed log-ratio can be represented as
Mpi = log2(Mixture/Jurkatt) = diβpi + εpi   (2)
where εpi represents measurement error and di = -1 if the
array is dye-swapped and 1 otherwise. We assume that the
εpi  are independent with mean zero and with probe
dependent standard derivations σp.
Design of experiment Figure 1
Design of experiment. This schematic represents the 12 
microarrays which were hybridized for each of the two-color 
platforms. Each arrow represents one array, with the head 
pointing to the sample labeled Cy5 (red) and the tail at the 
sample labeled Cy3 (green). The labels A1 to A6 and B cor-
respond to Table 1, where the exact mixing proportions are 
given.
Jurkat Mixture
A1
A2
A3
A4
A5
A6
B
B
B
B
B
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Note that the minimum value that the fold change Rp can
take is zero, for a probe whose transcript is present in Jur-
kat but completely absent in MCF7. The minimum possi-
ble value for the log-ratio βpi is therefore log2(1 - ci), the
log of the proportion of Jurkat in the mix. The titration
series introduces in this way a theoretical lower bound on
the range of possible log-ratios. The horizontal green lines
in Figure 2 represent this bound. Any M-value which falls
below this line does so in error. In general, all four plat-
forms maintain M-values consistently above the line, with
the greatest transgressions occurring for the spotted oligo-
nucleotide arrays.
The standard deviations σp and φp are the keys to quantify-
ing the precision of the platforms, because they represent
the array-to-array variability which is expected in measur-
ing log-ratios or log-expression values. Our approach is to
view equations (1) and (2) as nonlinear regression equa-
tions for the Epj and the Mpi, with unknown regression
parameters Fp and Jp for equation (1) and Rp for equation
(2). These equations are fitted by least squares to the avail-
able data for each probe to obtain estimated fold changes
and precisions for that probe. Regression equation (1)
was fitted to the 14 Epj data values for each Affymetrix
Selected MA plots for the titration series Figure 2
Selected MA plots for the titration series. M (log2 transformed fold change value) was plotted versus A (total intensity for 
that spot) for all genes on the arrays. Columns represent Spotted cDNA, Spotted oligonucleotide, Agilent and Affymetrix. The 
top row shows the A1 sample (MCF7) vs Jurkat, the second row shows the A3 mixture (88% MCF7, 12% Jurkat) vs Jurkat, the 
third row shows A5 (50% MCF7, 50% Jurkat) vs Jurkat and the bottom row is A6 (100% Jurkat) in a self-self hybridization. As 
expected the A1 sample shows the most differential expression in the series of arrays. Similarly, the A6 sample shows very lit-
tle differential expression. The green line represents the theoretical minimum fold change. No elements should report a fold 
change below this line.BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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probe-set and equation (2) was fitted to the 12 Mpi data
values for each probe on each two-color platform. A com-
plete worked example of the computations for one gene is
given in the Supplementary Materials [44]. Examples of
fitted curves are shown in Figure 3. In each case, the fitted
curve is that which minimizes the sum of squared devia-
tions of the data values from the curve. These calculations
yielded an estimated fold change Rp for each probe on
each two-color platform, which we call the consensus esti-
mate of the fold change between MCF7 and Jurkat for each
probe, because it is derived from the entire series of twelve
arrays. The consensus estimator is more precise than the
simple mean log-ratio that could be obtained from the
pure MCF7 and Jurkat arrays alone. The residual standard
error sp from each regression is our estimate for σp. Note
that   is a consistent and approximately unbiased esti-
mator for   by standard nonlinear least squares theory
[45]. For each Affymetrix probe-set, the intensities Fp and
Jp were estimated from the observed log-expression values
by non-linear least squares. This produced consensus esti-
mates of MCF7 and Jurkat expression for each probe from
the entire series fourteen arrays. The residual standard
error from each regression is our estimate of φp. In this
way, precision estimates were obtained for each probe on
each platform. Note that we applied least squares to the Epj
rather than to the un-logged expression values and to the
Mpi rather than the fold changes because the logged values
are more nearly symmetrically and normally distributed.
Dye effects
Another consideration with the two-color platforms is the
possibility of probe-specific dye bias, i.e., the tendency of
particular probes to incorporate one of the dyes more
readily than the other [46]. Dye-swaps were incorporated
into our design specifically to detect and balance such
effects. Equation (2) can be modified to allow for a dye-
effect as
Mpi = δp + diβpi + εpi   (3)
where the intercept term δp represents the probe specific
dye effect. If probe p does show a specific dye bias, then
including the intercept term will reduce the estimate of σp
as the new equation (3) more closely models the behavior
of the probe. If not, the estimated σp will on average
remain the same, although the residual degrees of free-
dom for the regression will decrease by one. Boxplots of
estimated   with and without the dye effect term are
given in Figure 4. It is clear that accounting for dye effects
improved the fits for all three platforms. For the Agilent
arrays the improvement is particularly noticeable, nearly
halving the median estimated  . Each of the two-color
platforms was hybridized with identical material from a
large pool of labeled mRNA, so the larger effect for Agilent
arrays is not due to the labeled material applied to the
arrays. We conclude that all two color platforms show
small but noticeable dye effects for a large proportion of
the probes. These dye effects can be estimated and
removed in a suitably designed experiment allowing infer-
ence to be conducted with improved precision and less
bias.
Precision of individual platforms
Comparing estimated σp values shows that the Agilent
platform is more precise, i.e., more repeatable, than the
two spotted platforms, which are very similar in precision.
The median σp s are 0.226, 0.218 and 0.0861 for the
cDNA, oligo and Agilent platforms respectively, after cor-
rection for dye-effects. These standard deviations corre-
spond to plus/minus fold changes of 17%, 16% and 6%
respectively. The step from the spotted platforms to Agi-
lent is substantial. The numbers suggest that (0.218/
0.0861)2 = 6.4 technical replicate oligo arrays are required
to estimate a typical fold change with the same precision
as one Agilent array.
Comparing the two-color platforms with Affymetrix is not
so straightforward, because σp measures the precision of
log-ratios while φp measures the precision of log-intensi-
ties. Quantitative comparison can only be done in the
context of specific experimental designs. If two Affymetrix
arrays are used to estimate log-fold changes between two
RNA targets, the standard deviation of the estimate for
probe p should be  φp, assuming the two arrays to be
independent and to have equal variances. With two-color
arrays, we need to distinguish between direct compari-
sons, in which the two RNA targets of interest are hybrid-
ized competitively to the same array, and indirect
comparisons, whereby one channel of each array is
hybridized with a common reference sample [47]. If two
two-color arrays are used to compare two RNA targets
indirectly via a common reference, the standard deviation
of the estimated log-fold change for probe p should be
σp, again assuming the arrays to be independent with
equal variances. On the other hand, if RNA targets are
compared directly on the same arrays, the standard devia-
sp
2
σp
2
σp
2
σp
2
2
2BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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tion would be σp using one array and σp/ u s i n g  t w o
replicate arrays [48]. Table 2 gives the precisions, i.e.,
standard deviations, with which a log-fold change would
be estimated from a minimal experiment for each of the
platforms. For the two-color platforms, results are given
for both a direct comparison using one array and for an
indirect comparison using two arrays. For Affymetrix, the
results assume a comparison between two arrays. Agilent
is the most precise platform, providing that the dye-effect
has been adjusted as indicated above. The spotted arrays
are nearly as precise as Affymetrix if they use direct com-
parison but much less precise if they do not.
Boxplots of the probe-wise standard deviations are shown
in Figure 5. For the two-color platforms the results assume
a direct design and are corrected for probe-specific dye
effects, so the situation is the same as for the top half of
Table 2. The conclusions are the same as for Table 2. The
Agilent arrays perform clearly the best, followed by
Affymetrix. For all the platforms there is a considerable
range of precisions across the probes. The full distribution
of probe-wise standard deviations for each platform is
shown as a density histogram in Supplementary Figure
1[44].
2
Fitted nonlinear curves for three example genes Figure 3
Fitted nonlinear curves for three example genes. The curves show the tend-lines predicted by the titration series of 
mixed RNA samples. The top three plots show curves fitted to the cDNA M-values, which are indicated as dots. Black dots are 
M-values, blue dots are dye-swap M-values which have been reversed in sign for the plot. The bottom three plots show curves 
fitted to the Affymetrix log-intensities, shown as dots.
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It is well known that the variability of expression meas-
ures can depend on the abundance of the gene transcript,
although the pre-processing methods we used are
designed in part to reduce this dependence. Figure 6 dis-
plays trend lines of   and 2  against mean A-value,
and these show generally decreasing trends of variability
versus intensity. The spotted arrays are far more variable
σp
2 ϕp
2
Boxplots of genewise variances for the two-color platforms before and after removing the gene-specific dye-effects Figure 4
Boxplots of genewise variances for the two-color platforms before and after removing the gene-specific dye-
effects. The orange boxplots give variances after correction for the gene-specific dye-effect and show that the variances are 
noticeably reduced. Lower values correspond to greater precisions. The improvement is most marked for the Agilent plat-
form. Each unit on the vertical axis corresponds to doubling of statistical information.
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Table 2: Standard deviation with which a typical log-fold change is measured using a minimal experiment.
Std Deviation
Design Platform Q1 Median Q3
Direct cDNA .121 .226 .353
Oligo .147 .218 .313
Agilent .063 .086 .122
Indirect cDNA .171 .319 .500
Oligo .208 .308 .442
Agilent .090 .122 .173
Affymetrix .131 .167 .211
The table gives the median standard deviation across probes together with the first and third quartiles. For the two-color platforms the design may 
be direct using one array or indirect via a common reference using two arrays. For Affymetrix, two arrays are used. The two-color calculations 
assume that estimates of probe-specific dye effects are available, .e.g., from a larger experiment including dye-swaps.BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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for lower intensity probes while the commercial platforms
maintain precision more evenly over the entire intensity
range. Agilent appears to have greater precision than
Affymetrix for probes in the middle range of intensities.
The precisions of the four platforms tend to converge for
the highest intensity probes. In Figure 6, the A-values for
the different platforms have been scaled to have the same
range.
Pure error and bias
It should be kept in mind when interpreting σp and φp that
they are overall measures of residual variation which
respond to both the variability between technical replicate
arrays (pure error) and any failure of the nonlinear regres-
sion curves to track the correct fold changes (bias).
Although the regression curves give a visually good fit to
the empirical data (Figure 3), there may nevertheless be
evidence for lack of fit. Such lack of fit might arise from a
failure of the microarray spot intensities to respond to
expression levels with perfect proportionality, or possibly
from small pipetting errors in preparing the titration
series. The pure error and bias components are additive
according to σ2 =   +  (Bias)2 for each probe. We
estimated the pure error and bias components by decom-
posing the residual sum of squares from each of the non-
σPure Error
2
Boxplots of genewise standard deviations with which a log-fold change is measured using the smallest possible experiment for  each platform Figure 5
Boxplots of genewise standard deviations with which a log-fold change is measured using the smallest possible 
experiment for each platform. Lower values correspond to greater precision and each unit of the vertical axis corre-
sponds to a doubling of statistical information. For the two-color platforms, values of log2  are plotted, corresponding to a 
direct comparison with one array after adjustment for probe-specific dye-effects. For Affymetrix, values of log2  are plotted 
corresponding to a comparison of two arrays. The median lines correspond to the direct design median values in Table 2, and 
the boxplot outlines correspond to the Q1 and Q3 given in Table 2.
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linear regressions (1) and (3) into pure error and lack of
fit components, and formed F-statistics to test for lack of
fit by dividing the lack of fit mean square by the pure error
mean square [49] (Section 3.4). The F-statistics were
found to be randomly distributed around unity (data not
shown), which is evidence that there is little or no system-
atic lack of fit. None of the F-statistics were statistically sig-
nificant after Bonferroni or Holm adjustment for multiple
testing across probes. As an extra precaution, in case lack
of fit exists but is not detected by the statistical tests
because of lack of power, we estimated the size of the lack
of fit variance component for each probe. For all probes
which show differentially expression between MCF7 and
Jurkat, the estimated lack of fit variance component
(squared bias) was either zero or extremely small com-
pared with the sums of squares due to the nonlinear
regression trend (data not shown). We conclude that the
nonlinear regressions describe the data more than ade-
quately for our purposes and that pure error is the domi-
nant component of the residual standard errors.
Concordance between platforms
We now turn to the question of systematic discordance
between the platforms, and for this purpose we need to
match probes corresponding to common genes across the
platforms. UniGene IDs were obtained for all probes,
using the UniGene build of 10 November 2003, and
Estimated precisions for different platforms as a function of expression level Figure 6
Estimated precisions for different platforms as a function of expression level. The curves are lowess trend curves 
fitted to the log2  values for the two-color platforms, corresponding to a direct comparison with one array with dye-effect 
adjustment, and to the logp 2  values for Affymetrix, corresponding to a comparison of two arrays. The horizontal axis is the 
average log-intensity over the A1 arrays for the two color platforms and over the A1 and B arrays for Affymetrix. Each unit on 
the vertical axis corresponds to a doubling of statistical information.
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3,636 genes were found to be present on all four plat-
forms. This was not sufficient to match probes across plat-
forms because most (56%) of the common genes were
represented by more than one probe, or probe set in the
case of Affymetrix, on at least one of the platforms. In
order to have an objective method of matching probes
uniquely across platforms, we chose for each gene the
probe on each platform with the highest average expres-
sion level. In other words, we chose the probe whose tran-
script is most highly represented in the cell lines used in
the study. Choosing a single representative probe on each
platform in this way was preferable to averaging multiple
probes for a given gene, for two reasons. Firstly, different
probes for the same gene on the same platform in many
cases showed quite different expression profiles, so that
averaging would be inappropriate. Secondly, taking aver-
ages of different numbers of probes would prevent the
platforms from being compared on the same basis.
The probes matched in this way showed broadly similar
behavior across the platforms but also noticeable differ-
ences (Figure 7). Genes are sorted by average MCF7 vs Jur-
kat log-ratio across platforms and columns correspond to
individual arrays progressing from A1 on the left to A6 on
the right. Dye-swapped arrays are un-swapped here in sil-
ico, i.e., are shown with M-values reversed in sign. As
expected, we observe a progressive reduction in the
number of differentially expressed genes from left to right,
although with somewhat more variability for the two
spotted platforms. The dye-effect noted above can be seen
in the alternating vertical stripes for the two-color plat-
forms, most noticeable for Agilent. The fold-change values
Rp estimated by the nonlinear regression are also in broad
agreement across the platforms, although there is consid-
erable scatter around equality (Figure 8). Points lying on
the y = 0 line for each pane in Figure 8 indicate probes
which fail to respond in that platform. All four platforms
seem to be returning a similar range of fold changes.
Cross-platforms correlations range from 0.6 between
cDNA and oligo to 0.75 between Agilent and Affymetrix
(Table 3). Affymetrix enjoys the best agreement with the
other platforms and cDNA the least. The oligo platform is
better correlated with Agilent and Affymetrix than the
cDNA platform despite being no more precise, suggesting
that the annotation of the Compugen probes is superior
to that of the cDNA probes.
By comparing the estimated fold changes with the plat-
form precisions, the cross-platform variability can be
decomposed into within-platform and between-platform
components. That is, the disagreement between any two
platforms can be separated into the variation inherent in
the two platforms and the variation caused by trying to
match probes across different technologies. Let M1 and
M2 be log-ratios for a particular gene from two technolo-
gies, i.e., M1 is the log-ratio observed on an array of plat-
form 1 and M2 is observed on an array of platform 2. For
Affymetrix, the log-ratio would be obtained by comparing
two arrays. The expected squared discrepancy between the
two log-ratios is the sum of variance and squared-bias:
E{(M1 - M2)2} = Variance + Bias2
=   +   + {log2 (cR1 + 1 - c) - log2(cR2 + 1 - c)}2
where   and   are the precisions   for this gene on
the two platforms and R1 and R2 are the fold changes Rp for
this gene on two platforms. For the A1 samples the pro-
portion of MCF7 is c = 1 so
E{(M1 - M2)2} =   +   + {log2(R1/R2)}2   (4)
The first two terms on the right-hand-side of equation 4
are the within-platform components while the third term
is the between-platform component, simply the squared
log-ratio of the fold-changes for this gene on the two plat-
forms. For most genes the third term turns out to be con-
siderably larger than the first two, particularly for genes
with larger fold-changes. Figure 9 plots each of the three
components of equation 4 against average log-fold
change for the 3,636 matched genes when comparing the
cDNA and Agilent platforms. For each component, the
plot is given as a loess trend line. The between-platform
component is larger than the within platform compo-
nents at all fold changes but becomes dominant as the
fold change increases. This relationship of within- and
between-platform variation is qualitatively the same for
all the combinations of platforms (data not shown). Pre-
vious work has shown that that matching genes across
platforms using sequences rather than UniGene IDs
reduces the differences seen between platforms [50]. It is
unlikely however that the qualitative picture in which the
between-platform component dominates would be mate-
rially changed.
Comparing pre-processing methods for Affymetrix data
All results presented above for the Affymetrix arrays use
expression values for each probe-set on each array pro-
duced by the RMA software algorithm [39]. Most Affyme-
trix expression results published in the literature have
been processed however using the Microarray Analysis
Suite (MAS) software from Affymetrix, now replaced by
GeneChip Operating Software [51]. Affymetrix has
recently developed a new preprocessing algorithm called
PLIER which incorporates some of the ideas associated
with RMA. To examine how these methods might change
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the results, we repeated all the analysis described above
using MAS and PLIER data. MAS 5.0 and PLIER were used
to extract the data using Affymetrix's recommended
parameters. For PLIER, quantile normalisation was used
and background subtraction was selected as PM-MM with
an offset of 24 = 16 added for variance stabilization at the
low intensity end (Affymetrix, personal communication).
The nonlinear model was fitted to the MAS 5 and PLIER
data and the variances   were recalculated. Investiga-
tion of the variances as a function of probe intensity
revealed that for both MAS 5 and PLIER the variance
increases at lower intensities (Figure 10). It can be seen
that both RMA and PLIER give more precise results than
MAS over the entire intensity range. The difference is sub-
stantial, corresponding to a four-fold increase in statistical
information for most probes. For high intensities, RMA
σp
2
Table 3: Cross-platform correlations of log-fold-changes for 3636 genes with probes on all four platforms. Each correlation 
corresponds to a pane in Figure 8.
cDNA Oligo Agilent Affy
cDNA 1.000 0.600 0.621 0.668
Oligo 0.600 1.000 0.687 0.707
Agilent 0.621 0.687 1.000 0.746
Affy 0.668 0.707 0.746 1.000
Heat map representations of gene expression across the titration series for 3636 genes common to all platforms Figure 7
Heat map representations of gene expression across the titration series for 3636 genes common to all plat-
forms. The horizontal axis corresponds to genes sorted from highest to lowest log-fold-change, according to an average of the 
four platforms for the A1 samples. The vertical axis corresponds to the 12 arrays (A1–A6 with dye-swaps) for the two-color 
platforms and to 14 arrays (A1–A6, B) for Affymetrix. Expression values are log-ratios: genes in red are Jurkat specific while 
genes in green are MCF7 specific. For Affymetrix, log-ratios are computed relative to the average of the Jurkat (A6, B) samples.
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and PLIER give almost identical variance measures. At low
intensities, RMA gives lower variances than PLIER. At
these intensities, RMA is also returning smaller fold
changes than PLIER, so it appears to be attenuating the
fold changes in this intensity range in order to achieve the
observed reduction in variability.
Discussion and conclusion
This article has described a new approach to evaluate the
reliability and accuracy of microarray platforms. The
method consists of an easy to construct titration series and
an associated statistical analysis. The global performance
of each microarray platform is determined by examining
Scatterplots of log-fold-change (log2Rp) for the 3636 genes with probes on all four platforms Figure 8
Scatterplots of log-fold-change (log2Rp) for the 3636 genes with probes on all four platforms. The plot shows 
broad agreement but also much disagreement between the four platforms.BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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the deviation of every probe on the array from its expected
behavior. This differs from most previous work where the
behavior of a gene is not an expected value, but rather is
subject to post hoc validation. Implicit in much previous
work is that the behavior of the whole array is inferred
from a relatively small number of validated expression
values.
A series of mixtures of two distinct RNA sources is used to
induce a graduated series of fold changes for each probe.
Our design uses one of the pure RNA samples as a com-
mon reference. This strategy ensures that the analysis can
be conducted entirely in terms of log-ratios for the two-
color platforms. Nonlinear regression is used to model the
expected pattern by which expression must change as a
function of the mixing proportions. This appears to be the
first application of nonlinear regression to microarray
data. The residual variation from the probe-wise regres-
sions provides a measure of precision and the lack of fit of
the curves measures deviation from response linearity for
each platform. The nonlinear regression approach
involves a novel concept, the idea that a consensus meas-
ure of fold change between the RNA sources can be
obtained from the entire series of arrays, even though
most of the arrays do not compare the pure samples. The
consensus fold change provides a measure of dynamic
range for each platform.
Within- and between-platform variance components for the oligo (red) and Agilent (green) platforms, as a function of average  log fold change Figure 9
Within- and between-platform variance components for the oligo (red) and Agilent (green) platforms, as a 
function of average log fold change. The total variation between platform can be shown to be made up of the variation 
within each platform plus the variation between platforms which arises from different probe technologies and matching probes 
across technologies. It can be seen that the variance from between platform measurements is much larger than the variation 
within any given platform. As expected, the disagreement increases as the magnitude of the fold change increases.
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For the titration series to be most effective, the two RNA
sources should contain many differentially expressed
probes including a wide range of fold changes. The RNAs
chosen in this article were MCF7 breast epithelial cells
[52] and Jurkat T-cells [53]. Previous work involving more
than 200 replicates of MCF7 versus Jurkat hybridization,
as part of a large microarray quality control program,
showed these lines to have a very divergent pattern of gene
expression consistent with their diverse tissues of origin
[54].
Four platforms were compared in this study. The ink-jet
printed two-color Agilent arrays and the single channel in
situ synthesized Affymetrix arrays gave the most consistent
results with respect to the predicted behavior. Academi-
cally produced spotted cDNA and oligonucleotide arrays
give somewhat more variable expression measurements,
as would be expected given their lower cost and quality
control. All the platforms yielded acceptable precision
however. Even the least precise cDNA platform gave a typ-
ical standard deviation of only 0.23 for measured log-
Variance as a function of intensity for Affymetrix preprocessing algorithms Figure 10
Variance as a function of intensity for Affymetrix preprocessing algorithms. The lowess trend curves of log2  ver-
sus the average log-intensity of MCF7 and Jurkat for the three pre-processing algorithms MAS5 (red), PLIER (blue) and RMA 
(black). It can be seen that MAS 5 gives higher variance than the other algorithms over all intensities while RMA and PLIER are 
almost identical at high intensities. At low intensities the RMA algorithm is more precise than PLIER, perhaps at the cost of 
greater bias.
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ratios from a single array (Table 2), which translates into
variation of ± 17% for the fold changes (20.226 = 1.17). Pre-
cision is intensity dependent for the spotted arrays but far
less so for the commercial arrays. The spotted arrays are
virtually as precise as the more expensive platforms for
high-intensity probes but the commercial platforms
appear better able to resolve differential expression at
lower expression levels.
The aim of this study was to evaluate the best-case sce-
nario for each platform. In practice, the platforms may
perform differently in other laboratories, particularly in
less experienced hands. The hybridization process is more
automated for the commercial platforms, especially
Affymetrix, so these platforms can be expected to give sta-
ble results for most laboratories. Our experience in ana-
lyzing microarray data from many laboratories suggests
that the academic array platforms are more subject to
operator and laboratory variability and to loss of quality
in inexperienced hands.
The effective precision of the two-color platforms was
found to be substantially improved by allowing for probe-
specific dye effects in the statistical model. This implies
that microarray experiments using two-color arrays
should be designed with sufficient alternation of dye
assignment to allow probe-specific dye effects to be iden-
tified. The results also imply that experimenters should
routinely allow for probe-specific effects in model-based
analyses of two-color microarray data [46,55,56].
It was a design criterion of our study that all two-color
microarrays were hybridized with identical labeled mate-
rial. Each point in the titration series was labeled as a pool
and then divided three ways between the platforms. This
approach was taken to control for any possible titration
inaccuracy or variation between probe labeling protocols.
The Agilent protocol calls for labeled riboprobes gener-
ated by a proprietary kit. It is possible that our decision to
standardize the labeling protocol across platforms may
have contributed to the large probe-specific dye effects
observed with the Agilent arrays. Nevertheless we have
found in separate studies that the two protocols produce
very similar results (data not shown), suggesting that any
bias introduced by the labeling protocol is likely to be
small.
Obtaining expression values from microarrays requires
several post-hybridization data analysis steps including
background correction and normalization. These steps are
often collectively called pre-processing to distinguish them
from subsequent data analysis steps. The methodology
developed in this article provides a means to objectively
compare different pre-processing methods for any given
platform. It is our intention to make the raw expression
data generated by this study publicly available. A website
will be established through which researchers can interac-
tively evaluate, for any of the four platforms, any pre-
processing method which is implemented as a function in
the R software environment. This is analogous to but
more general than the resource provided by the affycomp
software package for the Affymetrix platform [28].
It can be argued that the molecular biology literature has
been slow to appreciate the extent to which the choice of
pre-processing algorithm can impact on the precision of
microarray data. The emphasis has often been on filtering
highly variable spots rather than on ensuring low variabil-
ity in the first place. This study compared three pre-
processing methods for Affymetrix data and showed that
the differences are substantial. The propriety Affymetrix
pre-processing algorithm, the most frequently used in the
literature, was found to be easily the worst of the three
methods. The differences were so large that Affymetrix
quantified with MAS5.0 was the worst of all the platforms
considered in this study whereas Affymetrix quantified
with RMA was nearly the best. The loss of information of
MAS5.0 compared to RMA or PLIER varies from about 2-
fold for highly expressed genes to 16-fold at low intensi-
ties. Similarly unfavorable comparisons could have been
made with commonly used pre-processing methods for
the two-color platforms (data not shown). This highlights
the importance of using state-of-the-art pre-processing
methods to get reliable data from microarray technolo-
gies.
After probe matching, the four platforms were found to
broadly agree, with log-ratios across probes giving correla-
tions of around 0.7. The differences are large enough
though to establish that the platforms do differ systemat-
ically and, in fact, the majority of inter-platform disagree-
ment is due to systematic disagreement. This agrees with
qualitative observations in other studies [16,36]. A quan-
titative decomposition of variation into within- and
between-platform components is given for the first time.
In this study, probes were matched across platforms on
UniGene ID. Where there were multiple probes, or probe-
sets, on a platform for the same UniGene ID, the most
highly expressed probe was chosen. It is probable that bet-
ter agreement could have been obtained between the plat-
forms by BLAST searching [57] each individual probe
sequence and, where there were multiple probes, attempt-
ing to match probes based on sequence similarity or on
locus within a gene. Careful probe sequence matching of
this type is likely to be valuable in the future for improv-
ing cross-platform agreement, but it would be unlikely to
change the qualitative results presented in this study.BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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The presence of systematic disagreement between the plat-
forms emphasizes the need for improved annotation and,
in particular, for identification of the splice variants and
other isoforms for each gene. Systematic differences have
implications for how well published expression profiles
for a particular phenotype will be predictive using other
platforms [58]. It is widely accepted that there is a high
error rate in annotation of early cDNA libraries, and
despite some efforts at re-annotation, for example in the
NIA 15 K mouse clone set [59], errors have tended to
propagate along with the library. Recent work analyzing
Affymetrix probe-sets showed a surprisingly high level of
mismatches between probe sequences and the RefSeq
clone sequence the probes purportedly interrogate [30],
with only 62% of human U133A probe sequences being
perfectly matched. The consequence of mis-annotated or
mismatched probes has been shown in experiments
where correlations between platforms derived from
sequence verified probes are generally higher than for all
probes [30]. Recent technologies such as exon and tiling
arrays offer potential for elucidation of splice variants and
finer annotation of microarray probes [14,60-64]. Quan-
tifying the degree of between-platform disagreement for
each gene can serve to prioritize probes for re-annotation.
Methods
Microarrays
Analysis was performed on four microarray platforms,
two in-house and two commercial platforms. A spotted
human cDNA array with approximately 10,500 probes
[65] was printed at the Peter MacCallum Cancer Centre
(PMCC) in Melbourne. A spotted 19.2 k 70-mer oligonu-
cleotide array was also printed at the PMCC using oligos
supplied by Compugen. Commercial microarray plat-
forms were obtained from Agilent Technologies and
Affymetrix. In situ synthesised Human 1A Oligo arrays
(Agilent) printed with Agilent Sureprint Technology con-
tain 22,000 Oligonucleotide probes. Affymetrix U133A
arrays contain 17,000 in situ synthesised probe sets made
using photolithographic technology.
Cell culture and RNA extraction
MCF7, a breast epithelial cancer cell line [52], and Jurkat,
a human T cell leukemia cell line [53], were selected for
the experiment due to their diverse sites of origin. MCF7
cells were cultured in DMEM containing 10% FCS, and
Jurkat cells were cultured in RPMI supplemented with 10
mM HEPES and 10% FCS. MCF7 cells were harvested 42
hours after addition of fresh media. Briefly, cells were first
washed with 10 ml PBS prior to treatment with 3 ml
trypsin for 3 minutes at 37°C. Trypsin was inactivated
using 7 ml of DMEM media. Jurkat cells were collected 42
hours after adding fresh media by centrifugation. For both
cell lines cell pellets were first washed with PBS before
storage at -80°C. Total RNA was isolated using phenol-
chloroform (TRIzol, Invitrogen) extractions and purified
using column chromatography (RNeasy, Qiagen) accord-
ing to manufactures instructions. RNA quality was
checked by quantifying 260/280 and 260/230 ratios and
gel electrophoresis (data not shown). RNA was stored at -
80°C after ethanol precipitation.
RNA titration series
A titration series was made using MCF7 and Jurkat total
RNA (Table 1). To minimize variability introduced from
sample preparation, master mixes from each dilution
series point (A1–A6 and B) were prepared for the test sam-
ples and the reference. This master mix was used to aliq-
uot relevant amount of RNA needed for each labeling
reaction. The amount of RNA used depended on the spe-
cific protocols for the microarray platform.
Two colour microarray platforms (Human 10.5 K cDNA, 
Compugen 19.2 k Human oligonucleotide arrays and 
Agilent Human 1A oligo array)
For Human 10.5 k and Compugen 19.2 k Human oligo
arrays, 50 ug and 100 ug respectively of total RNA from
test samples (A1–A6) and reference (B) were reverse tran-
scribed using M-MLV Reverse transcriptase (Promega)
incorporating AA-dUTP (Sigma). cDNA was indirectly
labelled by coupling to Cy3 and Cy5 monoreactive dyes
(Amersham) according to the manufacturer's protocol. To
eliminate variations due to labeling, Cy3 and Cy5 labelled
cDNA products belonging to the appropriate reaction
number (A1–A6, and B) were pooled and proportionately
divided prior to combining of the test and the reference
sample for hybridisation. Repeats of each experiment
were dye swapped to account for variation arising due to
biased dye incorporation. After denaturation, cDNA
probes were hybridised with 3.1× SSC and 50% forma-
mide. Hybridisation was performed in a humidified
HyPro20  System (ThermoHybaid) at 42°C for 14–16
hours. Slides were washed with 0.5 × SSC/0.01% SDS (1
minute), then 0.5 × SSC (3 minutes) and finally 0.06 ×
SSC (3 minutes) at room temperature. For Agilent Human
1A oligo arrays, the same indirect labelling protocol
described above was used to label 50 ug of total RNA.
However hybridisation and subsequent washing of the
arrays were performed according to the manufacturer's
protocol. Briefly, 10× control mix (Agilent) and 2×
hybridisation buffer (Agilent) were added to denatured
cDNA probes to. Hybridisation was performed in an oven
(Robinson Scientific model 400) with rotator suited for
Agilent Microarray Hybridisation chambers at 60°C for
17 hours. Slides were washed with 6 × SSC/0.005% Triton
X-102 for 10 minutes at room temperature. Followed by
second wash with 0.1 × SSC/0.005% Trition X-102 for 10
minutes at 4°C. All two-colour arrays were scanned using
the Agilent Microarray Scanner System (G2565AA, Agilent
Technologies).BMC Bioinformatics 2006, 7:511 http://www.biomedcentral.com/1471-2105/7/511
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Single channel array (Affymetrix U133A GeneChip)
10 ug of total RNA from test samples (A1–A6) and refer-
ence (B) was used to prepare double strand (ds) cDNA
according to manufacturer's protocol. Replicates were per-
formed for each sample. Biotin labelled cRNA was synthe-
sized from ds cDNA using ENZO BioArray High Yield
RNA transcript kit (Affymetrix). cRNA from appropriate
reactions was pooled and divided before fragmentation.
30 ug of pooled cRNA was fragmented according to man-
ufacturer's instructions. Fragmented cRNA was then split
into two 15 ug aliquots, which was used to make hybrid-
ization solution. 2/3 of the hybridization mix, 10 ug of
cRNA, was hybridized at 45°C and 60 RPM for 16 hours
in an oven with a rotor (Hybridization oven 640, Affyme-
trix). Hybridized cRNA was then washed and stained
according to antibody amplification stain protocol for
Eukaryotic RNA. Slides were first washed with non-strin-
gent wash buffer (6× SSPE and 0.01% Tween-20) at 30°C
followed by stringent wash buffer (100 mM MES, 0.1 M
[NaH], 0.01% Tween-20) at 50°C. GeneChips were
stained with SAPE solution at 35°C prior to washing with
non-stringent wash buffer. GeneChips were then stained
with biotynlated anti-SAPE antibody at 35°C. Subsequent
staining with a second SAPE solution for biotynlated anti-
SAPE was followed by final wash with non-stringent wash
buffer. Chips were then scanned twice using 2500 Scan-
ner. Data was extracted using Affymetrix GeneChip® Oper-
ating Software (GCOS) Version 1.0.
Preprocessing and normalization
Expression data from the three two-color platforms was
pre-processed in the same way using methods which have
been shown to reduce variability [47]. Intensity data was
extracted from the red and green scanned images using the
SPOT software package [66]. The intensities were cor-
rected for background luminescence by subtracting the
"morph" background estimate [37] giving background
corrected red (R) and green (G) intensities for each spot
on the arrays. These were then summarized into log-ratios
M = log2R/G and average log-intensities A =
(log2R+log2G)/2 for each spot. The log-ratios were nor-
malized for each array using print-tip loess normalization
[38] implemented in the limma software package [56] for
R [67]. The Agilent ink jet technology doesn't use print
tips so global loess normalization was used for the Agilent
arrays.
Affymetrix arrays have a qualitatively different design than
the other platforms. Not only are they single instead of
two-channel but they use multiple probes, a "probe set",
to represent each gene or EST. The platform also contains
mismatch probes designed to test non-specific hybridiza-
tion. Pre-processing methods for this platform must there-
fore be different from the two-color platforms. We
extracted summary log-expression values for each probe
set on each array using the robust multi-array average
(RMA) algorithm, implemented in the affy software pack-
age for R, which has been shown to substantially reduce
variability especially for less highly expressed genes [39].
For comparison purposes, summary expression values
were also obtained using Affymetrix's proprietary pre-
processing software products MAS 5.0 and PLIER. In this
article, the term "probe" for the Affymetrix platform will
refer to a probe set.
In each case, pre-processing was applied to all probes on
the arrays, including control probes. The only exception
were blanks (ControlType = ignore) on the Agilent arrays,
which were removed prior to normalization. For all plat-
forms, control probes were removed prior to the analyses
described in RESULTS.
All arrays and hybridizations were examined by standard
quality assessment procedures [68] and were found to be
of excellent consistent quality.
Nonlinear regression
The main evaluation method developed in this paper is
based on nonlinear regression models which relate the
mixing proportions in the titration series to the expression
log-ratios, for the two-color platforms, and to the log-
expression values, for the Affymetrix platform. The
unknown parameters in the models, the actual expression
levels for each probe, were estimated for each probe and
for each platform using the nonlinear least squares (nls)
function in the R programming environment [69].
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